Careers  |  Sign In  |  Register

Latest in Oncology

Naval G. Daver, MD, an associate professor in the Department of Leukemia, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, highlights findings from the randomized phase 3 VIALE trial. The VIALE trial demonstrated significant overall survival and complete response with the...

CC-486: A Novel Maintenance Therapy for AML Patients Ineligible for Stem Cell Transplants

Dr. Daver on the Utility of Maintenance Therapy in AML

Naval G. Daver, MD, associate professor in the Department of Leukemia – Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the utility of maintenance chemotherapy in acute myeloid leukemia (AML) given the inconsistent data seen from many phase 2 clinical trials. Dr....
Naval G. Daver, MD, an associate professor in the Department of Leukemia, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses maintenance chemotherapy in acute myeloid leukemia (AML). Dr. Daver points to the May 2020 FDA priority review designation for oral azacitidine...